FDAsafety guidance83% confidence
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Bayer.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Gynecology · Endometrial Hyperplasia
- Sub-indication
- General
Related signal: Bayer's Mirena Investigated for Nonatypical Endometrial Hyperplasia Treatment